The company's Janus kinase 1 has met all co-primary and secondary endpoints in a pivotal Phase III study.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.